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Human mesenchymal stem cells (hMSCs) from bone marrow are
regarded as putative osteoblast progenitors in vivo and differentiate
into osteoblasts in vitro. Positive signaling by the canonical wingless
(Wnt) pathway is critical for the differentiation of MSCs into osteo-
blasts. In contrast, activation of the peroxisome proliferator-activated
receptor-γ (PPARγ)-mediated pathway results in adipogenesis. We
therefore compared the effect of glycogen-synthetase-kinase-3β
(GSK3β) inhibitors and PPARγ inhibitors on osteogenesis by hMSCs.
Both compounds altered the intracellular distributionof β-catenin and
GSK3β in a manner consistent with activation of Wnt signaling. With
osteogenic supplements, the GSK3β inhibitor 6-bromo-indirubin-3′-
oxime (BIO) and the PPARγ inhibitor GW9662 (GW) enhanced early
osteogenic markers, alkaline phosphatase (ALP), and osteoprotegerin
(OPG) by hMSCs and transcriptome analysis demonstrated up-regula-
tion of genes encoding bone-related structural proteins. At higher
doses of the inhibitors, ALP levels were attenuated, but dexametha-
sone-induced biomineralization was accelerated. When hMSCs were
pretreatedwithBIOorGWand implanted intoexperimentally induced
nonself healing calvarial defects, GW treatment substantially
increased the capacity of the cells to repair the bone lesion, whereas
BIO treatment had no signiﬁcant effect. Further investigation indi-
cated that unlikeGW,BIO induced cell cycle inhibition in vitro. Further-
more, we found that GW treatment signiﬁcantly reduced expression
of chemokines that may exacerbate neutrophil- and macrophage-
mediated cell rejection. These data suggest that use of PPARγ inhib-
itorsduring thepreparationofhMSCsmayenhance thecapacityof the
cells for osteogenic cytotherapy,whereas adenineanalogs suchasBIO
can adversely affect the viability of hMSC preparations in vitro and
in vivo.
osteogenesis | bone repair | tissue engineering
In vitro and in vivo hMSCs can differentiate into osteoblasts,adipocytes, and chondrocytes (1–6), but they also adopt a stromal
role, by providing extracellular matrix components, cytokines, and
growth factors for paracrine tissue support (7–9). As the pre-
sumptive precursors of osteoblasts, hMSCs and related cell lines
provide a convenient cell culture model for the study of osteogenic
tissue repair in an experimentally accessible system (10). Early
studies, employing cultures of osteogenic progenitors, have yielded
a wealth of information describing the molecular events that mod-
ulate osteogenic differentiation. A critical ﬁnding of these studies is
that positive signaling by the canonical wingless (Wnt) pathway is
essential for differentiation into osteoblasts (11–13). In the canon-
ical Wnt signaling pathway, secreted Wnt ligands bind to the
receptor frizzled (Frz) and the coreceptor lipoprotein-related pro-
tein 5 and 6 (LRP-5/6) on the target cell. Activation of Frz recruits
the cytoplasmic bridgingmolecule, disheveled (Dsh), so as to inhibit
the action of glycogen synthetase kinase-3β (GSK3β). Inhibition of
GSK3β decreases phosphorylation of β-catenin, preventing its
degradation by the proteasome. Stabilized β-catenin acts on the
nucleus by activating T cell factor/lymphoid enhancing factor
mediated transcription of target genes that elicit a variety of effects,
including induction of differentiation and, in some cases, pro-
liferation. Canonical Wnt signaling is tightly regulated by a combi-
nation of positive induction through the binding of the Wnt ligand
and negative regulation through numerous mechanisms including
the secreted glycoprotein dickkopf-1 (Dkk-1) (14). The clinical
signiﬁcanceofWnt signaling inosteogenesis has beenhighlightedby
reports that mutations in LRP5 that prevent Dkk-1 binding cause
abnormally highbonedensity (15), andmutations that renderLRP5
functionally null cause a formof osteoporosis (16). To date,most of
the studies that address the role of Wnt signaling in osteogenesis
have been carried out by using themurine system (17–19), and there
is evidence that Wnt signaling may have the contrary effect on
hMSCs (20). We therefore sought to investigate the role of Wnt
signaling and osteogenesis by human MSCs in more detail. We
compared an inhibitor of GSK3β that would be predicted to mimic
Wnt signaling through direct stabilization of β-catenin [6-bromo-
indirubin-3′-oxime (BIO)] and an inhibitor of PPARγ [GW9662
(GW)] that would be predicted to attenuate inhibitory crosstalk
from the adipogenic axis and, therefore, also enhanceWnt signaling
(21–23). We found that both BIO and GW increased in vitro min-
eralization, but expression of early osteogenicmarkers was biphasic,
with higher doses becoming inhibitory. When implanted into mice
harboring calvarial defects, hMSCs pretreated with GW sub-
stantially accelerated healing, whereas those pretreated with BIO
had no effect. Further investigation indicated that unlike GW, BIO
attenuatedhMSCrenewal in vitro. Furthermore,we found thatGW
treatment signiﬁcantly reduced expression of chemokines that may
exacerbate neutrophil- and macrophage-mediated cell rejection.
These data suggest that use of PPARγ inhibitors during the prep-
aration of hMSCs substantially and reliably enhances the capacity of
hMSCs forosteogeniccytotherapy,whereas adenineanalogs suchas
BIO have complicated and unpredictable effects on viability
and efﬁcacy.
Results
Effect of Dkk-1 and PPARγ Agonists on the Expression of ALP. To
conﬁrm that Wnt signaling is necessary for the differentiation of
hMSCs into osteoblasts, we incubated MSCs in osteoinductive
media containing no dexamethasone (dex) for 8 days andmeasured
activity of alkaline phosphatase (ALP). Although it is conventional
to add dexamethasone for osteogenesis, given its powerful pleio-
tropic effects and the observation that early osteogenic markers
such as ALP can be activated without its presence (Fig. S1A), initial
experiments were performed in the absence of dexamethasone.
When the Wnt inhibitor Dkk-1 was added to block canonical Wnt
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signaling, ALP activity was attenuated (Fig. 1A).We then examined
PPARγ activity on osteogenesis because the PPARγ activity
enhances adipogenesis while inhibiting the Wnt-mediated osteo-
genic axis of differentiation (20, 21). ALP function was dose-
dependently down-regulated upon incubationwith troglitazone and
also other synthetic PPARγ agonists (Fig. 1B and Fig. S1).
Effect of GSK3β and PPARγ Inhibition on Intracellular Redistribution
of GSK3β and β-Catenin. We examined whether inhibition of
GSK3β would mimic Wnt signaling through direct stabilization of
β-catenin, and whether inhibition of PPARγ would blunt inhib-
itory crosstalk from the adipogenic axis, therefore also resulting in
enhancement of Wnt signaling (Fig. 2A) (21–23). The inhibitors
BIO and GW were chosen because of their speciﬁcity for GSK3β
and PPARγ, respectively (Fig. 2A). Incubation of both inhibitors
with MSCs under osteogenic conditions resulted in increased
levels of nuclear β-catenin (Fig. 2 B and C) and depletion of
GSK3β from the cytoplasm (Fig. 2D). Interestingly, cytosolic
depletion of GSK3β occurred, even though the proposed mecha-
nism of BIO or GW does not predict up-regulation of a Wnt/Frz/
LRP/Dsh receptor complex. It is currently unclearwhetherGSK3β
is degraded or relocalized upon treatment with BIO/GW. None-
theless, both nuclear localization of β-catenin and depletion of
cytosolic GSK3β are consistent with enhancement of canonical
Wnt signaling. Furthermore, incubation of hMSCs in either BIO
or GW reduced nuclear levels of PPARγ, also suggesting that the
canonical Wnt axis was predominating in the treated cells.
Effect of GSK3β and PPARγ Inhibition on the Expression of ALP, OPG,
and Dkk-1. To examine whether the up-regulation of Wnt signaling
by the inhibitors affected early stage osteogenesis by MSCs, they
were incubated in osteogenic medium lacking dex but containing
BIO or GW. After 8 days of culture, ALP activity and the secretion
of OPG were measured. Both inhibitors induced the ALP activity,
but this was observed at low doses of inhibitor; in the case of BIO,
the maximal effect was observed between 100 and 200 nM and for
GW, the effect occurred at doses between 0.5 and 1.0 μM.At higher
doses, exceeding 400 nMBIOor 1.0 μMGW,ALP activity dropped
back to control levels (Fig. 3A). Secretion of OPG rose in a dose-
dependentmanner upon incubationwithBIO, but reachedmaximal
stimulation at 0.5 μM GW (Fig. 3B). It has been speculated that
arrest of canonical Wnt signaling occurs during terminal differ-
entiationof osteoprogenitor cells, andDkk-1 has been implicated in
this process (24, 25). Dkk-1 secretion was reduced in all cases, with
maximal inhibition occurring at concentrations that induced highest
ALP activity (Fig. 3C). Even though Dkk-1 levels were slightly
elevated with higher GW and BIO doses, they remained sig-
niﬁcantly lower than the control. A substantial reduction of hMSC
yield was evident when exposed to concentrations >400 nM BIO.
This effect did not seem to arise from canonical Wnt signaling
Fig. 1. EffectofDkk-1 (A) or thePPARγagonist, troglitazone (B),onALPactivity
and OPG secretion. ALP activity was visualized by staining and measured by
colorimetric assay. OPG was measured from the medium by ELISA. Values were
normalized to cell number. Data aremeans± SD (n = 6); *, P< 0.05, **, P< 0.01.
Fig. 2. In vitro effects of GW9662 and BIO on Wnt signaling in hMSCs. (A)
BIO and GW are predicted to up-regulate Wnt signaling by direct inhibition
of GSK3β or by ablating PPARγ-mediated negative crosstalk, respectively. (B)
Fluorescent microscopy of hMSCs with counterstained nuclei (pico-green;
Left) or cy-3 labeled anti-β-catenin stained nuclei (Right) (C) Immunoblots of
cytosolic GSK3β (C GSK3β), nuclear β-catenin (N β-cat), and nuclear PPARγ (N
−PPARγ) on extracts of hMSCs treated with BIO or GW. Blots were normal-
ized for cytosolic proteins with GAPDH (C GAPDH) and for nuclear proteins
by silver stain. (D) Immunoblots of whole cell and cytosolic extracts of hMSCs.
Fig. 3. hMSCs were incubated in osteogenic media with BIO or GW. After 8
days of culture, ALP activity was measured (A) and normalized to cell number
(D). OPG and Dkk-1 was measured from the media by ELISA (B and C). Data
are means ± SD (n = 6); *, P < 0.05, **, P < 0.01.
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because GW elicited the same effects on β-catenin, GSK3β redis-
tribution, and stimulation of early osteogenic markers without
reduction in cellular yield. Although BIO is highly speciﬁc for
GSK3β (26), the parent molecule, indirubin monooxime has been
shown to inhibit cyclin dependent kinases at high concentrations
(27). Cell cycle analysis demonstrated that hMSCs treated with
800 nM BIO exhibited a similar DNA proﬁle to those that are
heavily contact inhibited, suggesting that high doses of BIO inhibit
mitosis (Fig. S2A). The absence of apoptotic morphology, a pre-G1
peak, and no detectable levels of cleaved caspase 3 (Fig. S2B)
conﬁrmed apoptosis was also not responsible for the reduced
cell yield.
Effects of GSK3β and PPARγ Inhibition on the Transcriptome of
hMSCs. Inhibition of GSK3β and PPARγ appeared to increase the
level of Wnt signaling concomitantly with increased OPG secretion
and ALP activity. These observations suggested that the inhibitors
had enhanced the early stages of osteogenesis through acceleration
of canonical Wnt signaling at the expense of PPARγ activity. To
examine this phenomenon inmore detail, hMSCswere incubated in
osteogenicmedia lacking dex, but containing high (800 nMBIOand
10 μM GW) and low (200 nM BIO and 1.0 μM GW) doses of the
inhibitors. After 8 days of culture, RNA microarrays were per-
formed on the hMSCs. Initial inspection of the datasets demon-
strated that they shared similarities with a similar study involving
human ﬁbroblasts and Wnt3a, suggesting that canonical Wnt sig-
naling had been accelerated (Table S1). Irrespective of dose, dif-
ferentially transcribed genes clustered into two general groups with
strong statistical signiﬁcance (P < 0.0001 for all cases, Fig. S3)—(i)
up-regulated inGW- andBIO-treated cells compared to the vehicle
control and (ii) up-regulated in the vehicle control compared toBIO
and GW. Gene clusters were sorted into gene ontology (GO) tags
basedonknown function.ThemajorityofGOtags incluster I (Table
S2) consisted of membrane, mRNA processing, and intracellular
rearrangement-related functions as well as collagen and extrac-
ellularmatrix (ECM)groups.TheWnt/β-cateninGOgroupwas also
signiﬁcantly represented in this cluster. Upon examination of indi-
vidual fold-changes for differentially expressed ECM genes, it was
evident that collagens and ECM proteins found in bone tissue were
up-regulated, whereas those found in other tissues were reduced or
unchanged (Table S3). Of interest was the down-regulation of
matrixmetalloproteinase I, matrix gla-protein and oncostatinM, all
associated with inhibition of osteogenesis or bone catabolism.
Cluster II consistedmainly of genes responsible for steroid and lipid
processing (Table S4). Of note was the prevalence of prostaglandin
and lipid modifying enzymes in this cluster because these processes
often provide ligands for PPARγ (28) as well as enrichment of
sphingomyelin- and ceramide-related genes, which are strongly
associated with lipid and steroid homeostasis (29, 30).
Effect of GSK3β and PPARγ Inhibition on Late Stage Osteogenesis.
Extendedperiodsof incubation inBIOandGWin theabsenceofdex
did not induce biomineralization, so we therefore measured the
effect of the inhibitors in its presence. Initially, we examinedwhether
pretreatment of hMSCs with inhibitors BIO (200 and 800nM) and
GW(1.0 and10.0μM) in thepresenceof β-glycerophosphate (β-GP)
and ascorbate for 8 days, followed by 15 days in the same media
supplemented with dex, affected mineralization of the cultures. If
BIO or GW function to accelerate the cells through the immature
stages of osteogenesis and partially to maturity, hMSCs exposed to
these conditions would be expected to respond more rapidly to the
steroid-dependent mature osteoblast transition. After differ-
entiation, calcium content was visualized by Alizarin Red S (ARS)
staining, and the dye was extracted and quantiﬁed. At the doses
tested, and in a dose-dependent manner, BIO and GW enhanced
dex-induced differentiation into biomineralizing osteoblasts (Fig. 4).
We then examined whether withdrawal of the Wnt stimulus
caused by BIO andGWwas necessary for the hMSCs to progress to
a dex-dependent biomineralizing phenotype. Human MSCs were
precultured with BIO and GW in the presence of β-GP, ascorbate,
and dex for 17 days. Once again, inhibitor treatment enhanced dex-
inducedbiomineralization (Fig. 5), suggesting that theactionofBIO
and GW enhances the early stages of osteogenesis and removal of
the stimulus is not required to complete the process.Data fromboth
experiments suggest that Wnt modulation is necessary to induce an
early osteoprogenitor-like phenotype in hMSCs, and this process
can occur simultaneously with terminal differentiation.
Clotted Human Plasma Is a Biocompatible and Osteoinductive Vector
for Administration of hMSCs. In anticipation of in vivo experiments
testing the potential efﬁcacy of the inhibitor treated hMSCs for the
repair of bone, we examined a number of matrices for cell
administration. We found that clotted human plasma sustained
the survival and proliferation of hMSCs in vitro and also accel-
erated steroid-induced biomineralization. When monolayers of
hMSCs are partially covered with a meniscus of clotted human
plasma, the cells in contact with the plasma mineralize faster than
the uncovered portion of the monolayer when dex-containing
osteogenic media is provided (Fig. S4).
Fig. 4. MSCs were incubated in osteogenic media containing BIO or GW for
8 days. The cultures then received dex containing osteogenic media for a
further 15 days (Fig. S6A). Cultures were stained for calcium with ARS. For
semiquantiﬁcation, the stain was re-extracted and measured spectrophoto-
metrically. Both BIO (A) and GW (B) pretreatment enhanced mineralization.
Fig. 5. Cultures were incubated in osteogenic media containing dex and
BIO or GW (Fig. S6B). After 17 days, monolayers were stained for calcium
with ARS (A). For semiquantiﬁcation, the stain was re-extracted and meas-
ured spectrophotometrically (B).
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Effects of GSK3β and PPARγ Inhibition on Repair of an Experimental
Induced Cranial Defect in Mice.Given that BIO andGWaccelerated
osteogenic differentiation by human MSCs in vitro, we tested
whether the treated hMSCs could repair a critical bone defect in
vivo. Human MSCs were cultured in the presence of osteogenic
medium lacking dex, but containing BIO (200 and 800 nM) or GW
(1.0 and 10.0 μM). Calvarial lesions were generated in nude mice
and 1 × 106 hMSCs, mixed with human plasma, were applied, fol-
lowed by thromboplastin to initiate gelling. The scalp was sutured,
and the animals were allowed to heal. Initially, short-duration
experiments were performed to monitor distribution of the hMSCs
and to ensure the cells had survived the implantation process. GFP-
labeled hMSCs were administered, and mice were killed after 24 h.
Upon histological analysis, a substantial number of GFP-labeled,
healthyhMSCshad formeda thick layerover the injury andadjacent
bone tissue (Fig. S5A andB). The hMSCs could be readily detected
with an antibody for membrane localized human β-2 microglobulin
(Fig. S5 C and D). Robust antibody detection of unmanipulated
hMSCs, rather than lentiviral labeling, was favored in long-term
experiments because very low passage hMSCs could be used, rather
than genetically tagged preparations that had undergone a number
of passages. Long-term experiments were performed for 50 days,
with additional doses of hMSCs administered at day 14, 28, and 42
by direct injection of a plasma:hMSCmixture under the scalp (Fig.
6A). At day 50, the crania were explanted and x-ray images of the
calvarial lesions were taken. The digitized images were then ana-
lyzed densitometrically to quantify the degree of bone accrual (Fig.
6B). The lesioned side was compared with the contralateral side,
anddatawere expressed as the ratioof radio-opacity on the lesioned
side to the contralateral side. Surprisingly, GW, but not BIO, sig-
niﬁcantly improved the ability of MSCs to repair cranial lesions
when compared to MSCs that were not drug treated. Upon histo-
logical analysis, new bone formation was detected in the GW
groups, and in the case of the 10 μMGW group, marrow sinusoids
were evident in the newly formed bone (Fig. 7A), which could be
identiﬁed by tetracycline incorporation (Fig. 7B). In contrast, there
was no signiﬁcant sign of bone repair in the mock groups that
received plasma alone, and control hMSCgroups that received cells
treated with DMSO or BIO. When the sections were stained with
anti-β-2microglobulin, isolated clusters ofhMSCs fromonly control
andGWgroups were detected (Fig. 7C andD). However, nomore
than a few hundred cells could be counted throughout the entire
lesion, suggesting that the majority of cells had either died or
migrated away. In both control groups and in the GW-treated
groups, we detected blood vessels, demonstrating that GW treat-
ment had not affected the ability ofMSCs to initiate angiogenesis at
trauma sites (Fig. 8A).
Enhanced compatibility of the GW-treated hMSCs for the
osteogenic niche could explain the increased efﬁcacy, but not the
failure of the BIO-treated cells. However, upon further inspection
of the microarray data, a minor cluster was identiﬁed where genes
were profoundly down-regulated in GW-treated MSCs, and
notably up-regulated in BIO-treated MSCs as compared to the
control. This cluster was highly enriched for inﬂammatory medi-
ators, including IL-1, IL-8, and inﬂammatory chemokines of the
CXC family (Table S5). These data could be validated in most
cases byELISAanalysis of supernates from treated hMSCcultures
(Tables S6 and S7). Because nude mice are able to elicit a mac-
rophage- and neutrophil-mediated response, it is probable that the
GW-treated MSCs were protected by reduced expression of che-
moattractants. Furthermore, because we could not detect new
bone, hMSCs, or blood vessels in the BIO-hMSC treated calvaria,
it is likely that a combination of decreased viability and cell-
mediated rejection rendered these cells inactive.
Fig. 6. Three-millimeter-diameter calvarial defects were induced in nude
mice. One million hMSCs pretreated with BIO or GW were mixed with
plasma and administered to the bone lesion. Subsequent doses were injec-
ted at 14-day intervals until day 50 (Fig. S6C). (A) X-rays of explanted crania.
For the GW group, specimens representing the range of the standard
deviations are presented. (B) The ratio of lesioned to contralateral (intact
side) radio-opacity calculated by image analysis software. Data are means ±
SD (n = 6, n = 5 for mock).
Fig. 7. (A) Hematoxylin and eosin-stained longitudinal sections at the
diameter of the lesions. New bone can be seen in the GW-treated injuries.
(B) UV microscopy of transverse sections for tetracycline (new bone) depo-
sition (arrowed). (C) Immuno-histochemical staining of hMSCs embedded in
new bone of the GW-treated calvaria. Unstained murine osteoblasts (mOB)
are also visible. OST, osteoid; PO, periosteum.
Fig. 8. Blood vessels were identiﬁed on hematoxylin and eosin-stained sec-
tions (A, arrowed) corresponding to 0.5 mm either side of the diameter of the
lesion. (B) Six-micrometer sections were surveyed every 30 μm, and blood
vessel area was calculated. Data are means ± SD (n = 3 animals).
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Discussion
Cultures of hMSCs are inherently heterogeneous, with the indi-
viduals of the population possessing different propensities for
osteogenesis, chondrogenesis, adipogenesis, or proliferation. Het-
erogeneity can arise from the nature of the donor, the number of
past cell doublings, and cell density. Evidence suggests that the
history of a given hMSC, with respect to the number of cell dou-
blings, and past exposure to different levels of cell density, in most
cases can affect the propensity of a given cell to divide or differ-
entiate (31–33). This apparently stochastic distribution of cellular
characteristics can be controlled in part by the addition of cytokines,
growth factors, and/or drugs. Given that both Wnt signaling and
blunting of the adipogenic axis are necessary for the initiation of
osteogenic processes in MSCs, we sought to investigate the role of
small molecule inhibitors in controlling the events. We found that
Wnt signaling could be increased inMSCs by either direct inhbition
of GSK3β or by inhibiting the master regulator of adipogenesis,
PPARγ. These observations supported the widespread notion that
negative crosstalk occurs between the canonical Wnt and PPARγ
axis. At lower doses, we could signiﬁcantly enhance the expression
of early osteogenic markers in hMSCs by treatment with either
inhibitor, but osteogenic enhancement was attenuated at higher
doses. In contrast, when hMSCs were pretreated or simultaneously
treated with BIO or GW, and subjected to dex-dependent osteo-
genesis, mineralization was up-regulated in a dose-dependent
manner. A simple interpretation of these results leads to the con-
clusion that endogenous canonical Wnt signaling can enhance
osteogenesis. However, in light of an elegant series of experiments
carried out by Liu et al. (25), the mechanism seems more complex.
In this instance, canonical Wnts1 and 3a could inhibit ALP and
mineralization by hMSCs at high concentrations; however, when
hMSCs were subjected to a bimodal culture system where adipo-
genic and osteogenic supplements were available, canonical Wnt
signaling tipped the balance in favor of osteogenesis. It is possible,
therefore, the high-serum culture system used in our experiments
reﬂects a similar situation, with modest osteogenic and adipogenic
stimuli affecting abalanced steady stateon the cells.Thepresenceof
GWand BIO, therefore, disrupts the balance of the culture in favor
of the osteogenic lineage. In contrast, high concentrations of
PPARγ agonists in our osteogenic cultures containing dex initiate
adipogenesis rather than osteogenesis (Fig. S1C).
When implanted into experimentally induced calvarial defects in
mice, GW-treated hMSCs profoundly improved healing and
induced angiogenesis. Although vehicle-treated hMSCs could not
signiﬁcantly enhance bone repair, angiogenesis was also induced,
suggesting that even vehicle-treated hMSCs had survived at the site
for a duration sufﬁcient to initiate the process. BecauseBIO-treated
cells had neither an effect on bone repair or angiogenesis, and could
not be detected directly, it appeared that the cells rapidly died upon
administration or migrated from the site. Given the effects of BIO
on hMSCs in vitro, the former is most probable. Although the
efﬁcacy of GW-treated hMSCs is probably due to enhanced os-
teogenic propensity and angiogenic properties, substantial down-
regulation of immune chemokines is also likely to extend their
survival. Nevertheless, even the in vivo survival of GW-treated
hMSCs was transient, suggesting a support role for hMSCs where
the cells transiently up-regulate angiogenesis and inherent osteo-
genic capacity of the host’s tissue. In agreement with this observa-
tion, it has recently been demonstrated that a population of hMSCs
with an enhanced endogenous canonical Wnt signaling serves to
enhance synergistically the ostoegenic capacity of coadministered
hMSCs with a lesser degree of Wnt signaling (25).
Pharmaceutical modulation of canonical Wnt signaling can
increase the osteogenic capacity of hMSCs, but the small molecules
necessary for such a task have a broad spectrum of side effects that
may preclude the cells’ efﬁcacy in vivo. Nevertheless, we found that
hMSCs treated with GW, an inhibitor of PPARγ, had increased
their osteogenic propensity without blunting viability or their ability
to perform ancillary tasks such as angiogenic stimulation. The
modiﬁed cultures are essentially a combinationof stromal stemcells
and osteoblasts, with properties of both. Therefore, hMSCs pre-
pared in this manner are a unique and rationally designed cyto-
therapeutic with profoundly enhanced efﬁcacy for bone repair.
Experimental Procedures
For additional detail, refer to SI Experimental Procedures.
Tissue Culture. Iliac crest bone marrow aspirates (2 mL) were
drawn in accordance with institutional review board approval.
Mesenchymal stem cells were prepared from the mononuclear
fraction of the aspirates as described (31, 34).
Early Osteogenic Differentiation and Alkaline Phosphatase Assays.
MSCs were plated in six-well plates at an initial plating density of
100 cells/cm2 and cultured in standard complete media for 6 days
until semiconﬂuence (≈5,000 cells per cm2). Osteogenic base
media consisting of complete media containing 5 mg·mL−1 β-GP
and 50 μg·mL−1 ascorbate-2-phosphate (Sigma, Poole, Dorset,
UK), and the appropriate inhibitor or vehicle was then used to
induce early osteogenic differentiation. Assays were allowed to
proceed for 8–10 days with changes of media every 2 days. ALP
assays were performed as described (35).
Cell Cycle. Proﬁles were generated by ﬂuorescence-activated cell
sorting (Beckman Coulter FC500) and analyzed with Multi-
CycleAV (Phoenix Flow Systems) software.
Array Analysis. Transcriptome arrays were performed by using
Affymetrix apparatus and HG-U133 Plus 2.0 chips. Cytokine
arrays on conditioned media were performed by using a human
cytokine array (RayBiotech) and analyzed by using a digital imager
(Versadoc; Bio-Rad, Hercules, CA).
ELISAs. Assays for Dkk-1 and OPG were carried out by using
nonbiotinylated polyclonal capture antibodies and biotinylated
detection antibodies that were commercially acquired (R&D Sys-
tems, Minneapolis) on Nunc Immunosorp coated 96-well plates
(Fisher Lifesciences, Pittsburgh). The biotinylated capture anti-
bodies were detected by using horseradish peroxidase-conjugated
streptavidin and TMB substrate (Pierce, Rockford, IL).
Protein Extraction, Gel Electrophoresis, and Western Blotting.
Nuclear extracts were performed by Triton extraction and dif-
ferential centrifugation as described (36). Proteins were elec-
trophoresed and blotted onto nitrocellulose by using the Novex
electrophoresis system (Invitrogen, Carlsbad, CA).
Late-Stage Osteogenesis and ARS Staining. Mature osteogenic
assays were performed in six-well format as described (10).
Clotted Plasma Coculture. Conﬂuent monolayers of MSCs were
generated in wells of a 12-well tissue culture plate. Human
plasma was added to each well so as to cover ≈30% of the sur-
face area. After the plasma had clotted, osteogenic assays were
then performed by using standard media preparations.
Calvarial Lesions. MSCs were cultured in the presence of osteo-
genic base media containing the appropriate inhibitor or vehicle.
After 8 days, they were suspended in human plasma and
administered to nude mice that had received a circular lesion in
the cranium. Subsequent doses of cells were administered by
direct injection in plasma/thromboplastin mix.
X-ray Imaging and Quantiﬁcation. Cranial bones were imaged by x-
ray under anesthesia (Faxitron M20). Digital images were be
captured on a digital plate and processed on a phosphorimager
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reader (PMI; Bio-Rad) and processed by volume analysis soft-
ware (Quantity One; Bio-Rad).
Histochemistry and Immunocytochemistry. For β-catenin localization
studies, hMSCs were stained with a cy-3 conjugated anti-β-catenin
antibody (clone 15B8; Sigma, St. Louis), and nuclei were counter-
stainedwithpico-greendye (Invitrogen). Specimenswereprocessed
as parafﬁn blocks and 8-μm longitudinal sections were prepared,
deparafﬁnized, and rehydrated, then stained with hematoxylin and
eosin (Sigma). For immunocytochemistry, sections were probed
with an anti-human β-2-microglobulin antibody. An upright ﬂuo-
rescent microscope (Eclipse H600L; Nikon) ﬁtted with a high per-
formance camera (Retiga 2000R) and image analysis software
(NiSElements; Nikon) was employed for imaging.
Tetracycline Tracing of in Vivo Calcium Deposition. The tetracycline
was imaged by using an upright ﬂuorescent microscope (Eclipse
H600L; Nikon) ﬁtted with a high performance camera (Retiga
2000R) and analyzed by using NiSElements software (Nikon).
Embedding, sectioning, and mounting were carried out on
nondecalciﬁed material.
Semiquantitative Blood Vessel Measurements. Calvaria were ﬁxed,
decalciﬁed and sectioned in parafﬁn, and stainedwith hematoxylin
and eosin as described. Using NIS-Elements image analysis soft-
ware, the surface area of blood vessels in a deﬁned region of
interest was calculated and totaled (SI Experimental Procedures).
The values were expressed as the mean of total blood vessel area
from three animals per group.
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